IRVINE, Calif.–(BUSINESS WIRE)–Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Company”) (NYSE: RDY) concerning possible violations of federal securities laws.
If you purchased shares of Dr. Reddy’s and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
The investigation concerns whether Dr. Reddy’s and certain of its officers and/or directors violated federal securities laws. On November 6, 2015, the Company announced that it received a warning letter issued by the Food and Drug Administration concerning inadequate quality control standards at three of the Company’s manufacturing plants in India. On this news, shares of Dr. Reddy’s fell in value. On August 10, 2017, the Company disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. When this news was announced, shares of Dr. Reddy’s declined in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.